Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Loconsole

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Medicine|January 11, 2025
Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?Gaetano Licata, Eugenia Veronica Di Brizzi, Franco Castelli, et al.
Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Clinical, Cosmetic and Investigational Dermatology|January 13, 2023
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME StudyLuca Stingeni, Giovanna Malara, Andrea Conti, et al.
Acta Dermato-Venereologica|December 3, 2020
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME StudyMarina Talamonti, Giovanna Malara, Ylenia Natalini, et al.
Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|January 11, 2025
Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?Gaetano Licata, Eugenia Veronica Di Brizzi, Franco Castelli, et al.
Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Clinical, Cosmetic and Investigational Dermatology|January 13, 2023
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME StudyLuca Stingeni, Giovanna Malara, Andrea Conti, et al.
Acta Dermato-Venereologica|December 3, 2020
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME StudyMarina Talamonti, Giovanna Malara, Ylenia Natalini, et al.
Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Patient Preference and Adherence|November 26, 2021
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in ItalyGiuseppe Argenziano, Paolo Amerio, Maria Grazia Aragone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology Practical & Conceptual|November 14, 2025
GRINCH Index: Measuring Patient Satisfaction During Christmas Holiday Gift ProgramsGiulio Gualdi, Laura Bigi, Clara De Simone, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Pageof 8